NEW YORK, July 12, 2023 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of Biomea Fusion, Inc.: On June 23, 2023, Biomea Fusion presented data for its Type 2 diabetes drug candidate BMF-219 at a meeting of the American Diabetes Association. In response to…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.